Outlook Therapeutics director buys 5,000 shares
Outlook Therapeutics director buys shares on the open market.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Outlook Therapeutics director buys shares on the open market. Director Randy H. Thurman purchased 5,000 shares of Outlook Therapeutics common stock in an open-market transaction at $0.429 per share. Following this trade, he directly holds a total of 5,593 shares of the company.
Insider Trade Summary
Net Buyer: 5,000 shares
Net Buy
1 txn
Insider
THURMAN RANDY H
Role
Director
Bought
5,000 shs ($2K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 5,000 | $0.429 | $2K |
Holdings After Transaction:
Common Stock — 5,593 shares (Direct)
Key Figures
Shares purchased: 5,000 shares
Purchase price: $0.429 per share
Shares owned after transaction: 5,593 shares
+1 more
4 metrics
Shares purchased
5,000 shares
Open-market purchase of common stock
Purchase price
$0.429 per share
Price paid in the May 26, 2026 transaction
Shares owned after transaction
5,593 shares
Director’s direct holdings following the trade
Net buy shares
5,000 shares
Net-buy direction in transaction summary
Key Terms
open-market purchase, Common Stock, Form 4, net-buy
4 terms
open-market purchase financial
"transaction_action: open-market purchase"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Common Stock financial
"security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
net-buy financial
"netBuySellDirection: net-buy"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Outlook Therapeutics (OTLK) report for Randy H. Thurman?
Outlook Therapeutics reported that director Randy H. Thurman made an open-market purchase of 5,000 shares of the company’s common stock at $0.429 per share, as disclosed in a Form 4 insider trading report filed with regulators.
Was the Outlook Therapeutics (OTLK) insider trade an open-market purchase?
Yes, the transaction was an open-market purchase. The Form 4 classifies it with code P, indicating a purchase in the open market or a private transaction, with 5,000 common shares bought at a price of $0.429 per share.
Did the Outlook Therapeutics (OTLK) Form 4 show any insider sales?
No, the Form 4 for Outlook Therapeutics shows only a net buy transaction. It reports one open-market purchase of 5,000 shares by director Randy H. Thurman and no corresponding sales or dispositions in this specific insider filing.
What does the net-buy summary indicate in the Outlook Therapeutics (OTLK) Form 4?
The net-buy summary indicates that insiders covered by this Form 4 collectively bought 5,000 shares and sold none. For this filing, that reflects Randy H. Thurman’s single open-market purchase of 5,000 Outlook Therapeutics common shares at $0.429 each.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates